Q1 EPS Estimate for Sage Therapeutics Increased by Analyst

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Research analysts at Wedbush increased their Q1 2025 earnings per share (EPS) estimates for Sage Therapeutics in a note issued to investors on Wednesday, November 20th. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will post earnings of ($1.31) per share for the quarter, up from their previous forecast of ($1.38). Wedbush currently has a “Neutral” rating and a $8.00 target price on the stock. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.50) per share. Wedbush also issued estimates for Sage Therapeutics’ Q2 2025 earnings at ($1.16) EPS, Q3 2025 earnings at ($1.18) EPS, Q4 2025 earnings at ($1.18) EPS, FY2025 earnings at ($4.83) EPS, FY2026 earnings at ($3.31) EPS, FY2027 earnings at ($0.79) EPS and FY2028 earnings at ($0.29) EPS.

SAGE has been the subject of a number of other research reports. HC Wainwright reaffirmed a “neutral” rating and issued a $14.00 target price on shares of Sage Therapeutics in a research report on Wednesday, November 20th. Royal Bank of Canada upgraded Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price target on the stock in a research note on Thursday, November 21st. Truist Financial reduced their price objective on Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating for the company in a research report on Wednesday, October 30th. Needham & Company LLC reissued a “hold” rating on shares of Sage Therapeutics in a research report on Wednesday, November 20th. Finally, Robert W. Baird reduced their price target on shares of Sage Therapeutics from $13.00 to $9.00 and set a “neutral” rating for the company in a research report on Wednesday, October 9th. Three equities research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, Sage Therapeutics has an average rating of “Hold” and a consensus price target of $12.83.

Sage Therapeutics Stock Up 2.1 %

SAGE opened at $5.28 on Monday. The stock has a market capitalization of $322.98 million, a price-to-earnings ratio of -0.93 and a beta of 0.92. The firm has a 50 day moving average price of $6.70 and a 200-day moving average price of $9.00. Sage Therapeutics has a twelve month low of $4.62 and a twelve month high of $28.26.

Sage Therapeutics (NASDAQ:SAGE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.52) by ($0.01). The business had revenue of $11.87 million during the quarter, compared to analysts’ expectations of $10.80 million. Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. Sage Therapeutics’s quarterly revenue was up 337.1% compared to the same quarter last year. During the same period last year, the firm posted ($2.81) EPS.

Hedge Funds Weigh In On Sage Therapeutics

Several large investors have recently made changes to their positions in SAGE. Vanguard Group Inc. grew its position in shares of Sage Therapeutics by 8.1% during the first quarter. Vanguard Group Inc. now owns 5,751,373 shares of the biopharmaceutical company’s stock worth $107,781,000 after purchasing an additional 432,013 shares in the last quarter. RTW Investments LP grew its holdings in Sage Therapeutics by 2.0% during the 3rd quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company’s stock valued at $40,372,000 after buying an additional 111,123 shares in the last quarter. State Street Corp grew its holdings in Sage Therapeutics by 18.2% during the 3rd quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock valued at $21,127,000 after buying an additional 451,377 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Sage Therapeutics by 0.3% during the third quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company’s stock valued at $8,975,000 after buying an additional 3,757 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Sage Therapeutics by 69.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 811,934 shares of the biopharmaceutical company’s stock worth $15,217,000 after buying an additional 333,805 shares in the last quarter. 99.22% of the stock is currently owned by hedge funds and other institutional investors.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.